Pulmonx Co. (NASDAQ:LUNG) Receives Average Recommendation of “Moderate Buy” from Brokerages

Pulmonx Co. (NASDAQ:LUNG) has received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $12.75.

A number of equities research analysts recently issued reports on LUNG shares. Citigroup reiterated a “neutral” rating and issued a $7.50 price objective (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Wells Fargo & Company decreased their price target on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th.

Pulmonx Stock Performance

Shares of LUNG stock opened at $7.48 on Monday. Pulmonx has a fifty-two week low of $5.46 and a fifty-two week high of $10.01. The stock’s 50-day moving average is $6.96 and its two-hundred day moving average is $6.94. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The firm has a market cap of $297.67 million, a P/E ratio of -5.19 and a beta of 0.50.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.12. The firm had revenue of $23.77 million for the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. Analysts predict that Pulmonx will post -1.55 earnings per share for the current fiscal year.

Insider Activity

In related news, General Counsel David Aaron Lehman sold 22,355 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.65, for a total transaction of $171,015.75. Following the completion of the transaction, the general counsel now directly owns 175,496 shares in the company, valued at $1,342,544.40. This represents a 11.30 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Geoffrey Beran Rose sold 5,779 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.13, for a total transaction of $41,204.27. Following the transaction, the insider now owns 285,278 shares in the company, valued at approximately $2,034,032.14. The trade was a 1.99 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 127,986 shares of company stock valued at $986,673. 5.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of LUNG. GSA Capital Partners LLP bought a new stake in Pulmonx in the 3rd quarter valued at $537,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Pulmonx during the 3rd quarter valued at about $480,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Pulmonx by 5.2% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,114,297 shares of the company’s stock valued at $9,238,000 after acquiring an additional 55,279 shares during the period. Charles Schwab Investment Management Inc. raised its position in Pulmonx by 5.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 313,169 shares of the company’s stock worth $2,596,000 after purchasing an additional 15,543 shares in the last quarter. Finally, FMR LLC lifted its stake in Pulmonx by 11.2% during the third quarter. FMR LLC now owns 5,872,882 shares of the company’s stock worth $48,686,000 after purchasing an additional 591,859 shares during the period. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.